XT
AKRO

XTX Topco’s Akero Therapeutics AKRO Stock Holding History

XTX Topco’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,740
Closed -$308K – 2240
2024
Q3 		$308K Buy
+10,740
New +$280K 0.02% 1160
2023
Q4 		– Sell
-8,122
Closed -$411K – 1535
2023
Q3 		$411K Buy
+8,122
New +$378K 0.07% 521
2023
Q2 		– Sell
-7,470
Closed -$286K – 1375
2023
Q1 		$286K Buy
+7,470
New +$333K 0.06% 691
2022
Q3 		– Sell
-13,305
Closed -$126K – 1076
2022
Q2 		$126K Buy
+13,305
New +$139K 0.05% 588

Other funds holding AKRO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

XTX Topco's AKRO Position: Q4 2024 in Review

XTX Topco sold out of Akero Therapeutics (AKRO) in Q4 2024, closing a stake of 10,740 shares — an estimated $308K sold.

XTX Topco first reported a position in AKRO in Q2 2022 and held it in 4 quarters. The position peaked at $411K in Q3 2023. 191 funds tracked by Wall St. Rank hold AKRO as of Q4 2024.

  • XTX Topco reported no remaining Akero Therapeutics position as of Q4 2024 after selling out during the quarter.
  • XTX Topco sold 10,740 Akero Therapeutics shares in Q4 2024, an estimated $308K.
  • XTX Topco first reported a position in Akero Therapeutics in Q2 2022 and held it in 4 quarters.
  • XTX Topco's Akero Therapeutics position peaked at $411K in Q3 2023.
  • 191 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2024.

Based on XTX Topco's 13F filing for Q4 2024, filed 13 Feb 2025.